Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05483283 · ClinicalTrials.gov registry record · NA
Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care
A NA study of Breast Cancer, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 600
- Enrollment target
- 1
- Study location
NCT05483283: Recruiting NA study of Breast Cancer, sponsored by University of Illinois at Chicago.
NCT05483283 is a NA study of Breast Cancer that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 600 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05483283, a NA study of Breast Cancer, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigator and study staff will identify, recruit and randomize Latina participants with elevated genetic and Social Determinants of Heath (SDH) risks. Within 1 week of enrollment, all Latina Aim 1 participants in both study arms will engage in three 30-minute, individual, phone-based sessions with the study team across 3 consecutive weeks
Primary Outcome
Number of participants that undergo risk-based BC screening per ACS guidelines versus the control group
Conditions Studied
Interventions
- OTHER SOC
- OTHER Empowerment and Navigation
Study Locations (1)
Illinois
- University of Illinois - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2023-01-18 |
| Est. Completion | 2027-09 |
| Phase | NA |
What NCT05483283 shows while recruiting
NCT05483283 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which SOC is the first listed.
NCT05483283 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05483283 about?
NCT05483283 is a clinical study titled "Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care". The investigator and study staff will identify, recruit and randomize Latina participants with elevated genetic and Social Determinants of Heath (SDH) risks. Within 1 week of enrollment, all Latina Aim 1 participants in both study arms will engage in three 30-minute, individual, phone-based sessions...
What is the current status of trial NCT05483283?
This trial is currently recruiting. It is a NA study. The enrollment target is 600 participants. The study started on 2023-01-18. Estimated completion is 2027-09.
What conditions does trial NCT05483283 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05483283?
The interventions under investigation include: SOC (OTHER), Empowerment and Navigation (OTHER).
Who is sponsoring clinical trial NCT05483283?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05483283 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05483283's enrollment target sits among peer trials
600 177th of 1224 higher than 1,044 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI